EGFR and lung cancer: Overall, the previous reviewed data, show that RKIP is an important modulator of relevant intracellular signaling pathways (including MAPK, which is controlled by EGFR), is both a driver and predictor of therapy response in lung cancer (Table 1), and has an important role in normal lung homeostasis.